Achillion Pharmaceuticals Inc. (ACHN)
Symbol Info
Listed Symbol ACHN
Name Achillion Pharmaceuticals Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $-
Latest Fiscal EPS $-0.51
Price Info
21 Day Moving Average $4.0410
21 Day EMA $4.354350
50 Day Moving Average $4.2172
50 Day EMA $4.092420
200 Day EMA $3.480820
200 Day Moving Average 3.186400
52 Week High $6.44
52 Week Low $1.29
52 Week Change $100.328896
Alpha -0.001218
Beta 1.4808
Standard Deviation 0.208775
R2 0.059329
Periods 60
Share Information
10 Day Average Volume 8,224,146
20 Day Average Volume 5,273,254
30 Day Average Volume 3,892,217
50 Day Average Volume 2,765,027
Outstanding Shares 139,692,908
Float Shares 139,322,038
Percent Float 99.73%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 250
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months 7,492,885
Institute Holdings Percent -
Institute Sold Previous 3 Months 6,689,187
Insider Holdings Date
Insider Bought Previous 3 Months -
Insider Holdings Percent -
Insider Sold Previous 3 Months -
Insiders Shares Owned 370,870
Price Change
7 Day Price Change $2.4600000
7 Day Percent Change 67.77%
21 Day Price Change $2.4200000
21 Day Percent Change 65.94%
30 Day Price Change $2.2800002
30 Day Percent Change 59.84%
Month To Date Price Change $2.4900
Month To Date Percent 69.17%
90 Day Price Change $3.670000
90 Day Percent Change 151.65%
Quarter To Date $2.490000
Quarter To Date Percent 69.17%
180 Day Price Change $3.160000
180 Day Percent Change 107.85%
200 Day Price Change $3.040000
200 Day Percent Change 99.67%
Year To Date $4.500000
Year To Date Percent 283.02%
Profile
Description Achillion Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on advancing oral small molecule complement system inhibitors into late-stage development and commercialization.
Details
Issue Type CS
Market Cap $850,729,810
Sec Type EQS
Auditor PricewaterhouseCoopers LLP
Total Shares Outstanding 139,692,908
CEO Joseph Truitt
Employees 56
Last Audit UQ
Classification
CIK 0001070336
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 1777 Sentry Parkway West
Building 14, Suite 200
Blue Bell, PA 19422
Website http://www.achillion.com
Facisimile
Telephone +1 215 709-3040
Email
Key Ratios
Profitability
EBIT Margin -
EBITDA Margin -
Pre-Tax Profit Margin -
Profit Margin Cont -
Gross Margin -
Profit Margin TOT -
Income Statements
Revenue $-
Revenue Per Share $-
Revenue 3 Years $-
Revenue 5 Years $-
Valuation Measures
PE Ratio -
Enterprise Value $270,891,468
Price To Sales -
Price To Free Cash -12
PE High Last 5 Years -
Price To Book 2.3
Price To Cash Flow 128.4
PE Low Last 5 Years -
Price To Tangible Book 2.3
Financial Strength
Total Debt To Equity 0.0
Int Coverage -2,285.1
Current Ratio 14.6
Leverage Ratio 1.1
Quick Ratio 14.4
Long Term Debt To Capital -
Assets
Receivables Turnover -
Invoice Turnover -
Assets Turnover -
Management Effectiveness
Return Assets -26.08
Return On Equity -27.32
Return On Capital -29.26
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
ACHN
Achillion ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.